HighTower Advisors’s Precigen PGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1,000
Closed -$200 3603
2022
Q4
$200 Hold
1,000
﹤0.01% 3317
2022
Q3
$18K Buy
+1,000
New +$2.11K ﹤0.01% 2981
2022
Q1
Sell
-1,000
Closed -$23K 3624
2021
Q4
$23K Sell
1,000
-99,000
-99% -$426K ﹤0.01% 3096
2021
Q3
$78K Buy
+100,000
New +$576K ﹤0.01% 2877

Other funds holding PGEN

HighTower Advisors's PGEN Position: Q1 2026 in Review

HighTower Advisors increased its Precigen (PGEN) stake by 9.2% in Q1 2026, buying an estimated $39.4K and bringing the position to 114,152 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #2827.

HighTower Advisors first reported a position in PGEN in Q1 2014 and has held it in 46 quarters since. The position peaked at $3.94M in Q3 2018. 205 funds tracked by Wall St. Rank hold PGEN as of Q1 2026.

  • HighTower Advisors held 114,152 shares of Precigen worth $442K as of Q1 2026.
  • HighTower Advisors bought 9,592 Precigen shares in Q1 2026, an estimated $39.4K.
  • Precigen made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2827 holding.
  • HighTower Advisors first reported a position in Precigen in Q1 2014 and has held it in 46 quarters since.
  • HighTower Advisors's Precigen position peaked at $3.94M in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Precigen as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.